260 493

Cited 12 times in

Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells

Authors
 Joon Jeong  ;  Kyung Sun Lee  ;  Yang-Kyu Choi  ;  Young Ju Oh  ;  Hy-De Lee 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.26(12) : 1569-1575, 2011 
Journal Title
JOURNAL OF KOREAN MEDICAL SCIENCE
ISSN
 1011-8934 
Issue Date
2011
MeSH
Animals ; Apoptosis/drug effects ; Bone Density Conservation Agents/pharmacology ; Bone Neoplasms/prevention & control ; Bone Neoplasms/secondary* ; Bone and Bones/drug effects ; Bone and Bones/pathology ; Breast Neoplasms/drug therapy* ; Breast Neoplasms/pathology* ; Diphosphonates/pharmacology* ; Female ; Humans ; Imidazoles/pharmacology* ; Mice ; Mice, Nude ; Xenograft Model Antitumor Assays
Keywords
Bone Metastasis ; Breast Neoplasms ; Prevention ; Zoledronic Acid
Abstract
Bisphosphonates are used routinely to reduce bone-related events in breast cancer patients with bone metastasis. We evaluated the effects of zoledronic acid, a third generation, nitrogen-containing bisphosphonate, to prevent bone metastasis in breast cancer. Zoledronic acid or vehicle alone was administered to nude mice either simultaneously or after intracardiac injection of human breast cancer MDA-MB-231 cells. Nude mice treated with zoledronic acid at early time points showed a lower incidence of bone metastases than did vehicle-treated nude mice, but these differences were not statistically significant. Only 37.5% of mice treated with zoledronic acid at the time of tumor cell inoculation developed bone metastases compared to over 51.8% of mice receiving vehicle alone (P = 0.304). Cell count of apoptosis confirmed by immunohistochemical staining in metastatic bone tissue significantly increased in the zoledronic acid-treated groups compared to non-treated group (1,018.3 vs 282.0; P = 0.046). However, metastatic tumor cells, which invade soft tissue around the bone, did not show extensive apoptosis; there were no differences between the zoledronic acid-treated and control groups. These results suggest that zoledronic acid increases apoptosis of metastatic breast tumor cells in the bone and could therefore reduce metastatic tumor burden. These results support the use of zoledronic acid to reduce the incidence of bone metastasis in breast cancer.
Files in This Item:
T201104702.pdf Download
DOI
10.3346/jkms.2011.26.12.1569
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
Yonsei Authors
Oh, Young Ju(오영주)
Lee, Hy De(이희대)
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/94775
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links